I thought the second point in the summary of the AGM Presentation is an intetesting one.
• HIV‐1/BIT225• BIT225‐009 Phase 2 trial provides clear clinical evidence that BIT225 is having a unique effect inindividuals infected with HIV‐1
• Engaged with the right potential partners, with the right legal/commercial deal‐making skills in place
• This is not a fast process; but we are focused an achieving a commercial outcome
• Preclinical Programs
• HBV has promise as a preclinical candidate for joint development.
• BIT225 results validate the platform; potential to facilitate funded developments by partners for“other” viral diseases
• Regional Licensing
• HCV in China remains a significant development opportunity – “cost‐conscious” market combinedwith the high rate of co‐infection HCV & HBV requires different approach than used in the USA
- Forums
- ASX - By Stock
- updates about the deals
I thought the second point in the summary of the AGM...
-
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
3.4¢ |
Change
0.001(3.03%) |
Mkt cap ! $30.67M |
Open | High | Low | Value | Volume |
3.4¢ | 3.4¢ | 3.3¢ | $632 | 18.85K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 287617 | 3.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.5¢ | 37989 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 287617 | 0.033 |
3 | 215000 | 0.032 |
2 | 332500 | 0.031 |
8 | 540666 | 0.030 |
1 | 100000 | 0.029 |
Price($) | Vol. | No. |
---|---|---|
0.035 | 10000 | 1 |
0.036 | 65500 | 1 |
0.037 | 537816 | 2 |
0.039 | 490546 | 3 |
0.040 | 113240 | 2 |
Last trade - 13.36pm 19/07/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |